Novel compound heterozygote variants: c.4193_4206delinsG (p.Leu1398Argfs*25), c.793C > A (p.Pro265Thr), in the CPS1 gene (NM_001875.4) causing late onset carbamoyl phosphate synthetase 1 deficiency-Lessons learned
- PMID: 36466970
- PMCID: PMC9709223
- DOI: 10.1016/j.ymgmr.2022.100942
Novel compound heterozygote variants: c.4193_4206delinsG (p.Leu1398Argfs*25), c.793C > A (p.Pro265Thr), in the CPS1 gene (NM_001875.4) causing late onset carbamoyl phosphate synthetase 1 deficiency-Lessons learned
Abstract
Carbamoyl phosphate synthetase 1 (CPS1) deficiency is an autosomal recessive urea cycle disorder with varying presentations. Patients with a neonatal-onset phenotype are initially healthy but develop severe hyperammonemia days after birth and often have poor or lethal outcomes, while patients who present later in life may exhibit less severe clinical manifestations. CPS1 deficiency is rarely found on newborn screening because most states do not screen for this disease due to the technical difficulties. We report a case of an 11-year-old, previously healthy girl who presented with hyperammonemia and acute psychosis after eating large amounts of meat at summer camp. A diagnosis of carbamoyl phosphate synthetase type 1 deficiency was suspected by biochemical profiles and confirmed by molecular analysis. Subsequent follow up lab results revealed ammonia to be only 25-39 μmol/L shortly after glutamine reached levels as high as 770-1432 μmol/L with concurrent alanine elevations, highlighting the compensating mechanisms of the human body. Her initial hospital course also demonstrated the importance of continuous renal replacement therapy (CRRT) in avoiding rebound hyperammonemia and high glutamine and the benefits of intracranial pressure (ICP) monitoring, providing 3% hypertonic saline and temperature control to avoid fever in treating cerebral edema. Carglumic acid was not considered helpful in this case, with BUN levels ranging between 2 and 4 mg/dL after administration.
Keywords: Alphaketoglutarate; Carbamoyl phosphate synthetase 1 deficiency; Glutamine; Hyperammonemia; Nacetylglutamate synthetase deficiency; Urea cycle disorder.
© 2022 Published by Elsevier Inc.
Conflict of interest statement
We have no conflict of interests to declare.
Figures




Similar articles
-
Clinical and genetic analysis of a case of late onset carbamoyl phosphate synthase I deficiency caused by CPS1 mutation and literature review.BMC Med Genomics. 2023 Jun 26;16(1):145. doi: 10.1186/s12920-023-01569-w. BMC Med Genomics. 2023. PMID: 37365635 Free PMC article. Review.
-
Clinical features and CPS1 variants in Chinese patients with carbamoyl phosphate synthetase 1 deficiency.BMC Pediatr. 2024 Aug 22;24(1):539. doi: 10.1186/s12887-024-05005-5. BMC Pediatr. 2024. PMID: 39174957 Free PMC article.
-
Fatal hyperammonemia and carbamoyl phosphate synthetase 1 (CPS1) deficiency following high-dose chemotherapy and autologous hematopoietic stem cell transplantation.Mol Genet Metab. 2015 Mar;114(3):438-44. doi: 10.1016/j.ymgme.2015.01.002. Epub 2015 Jan 24. Mol Genet Metab. 2015. PMID: 25639153
-
A constitutive knockout of murine carbamoyl phosphate synthetase 1 results in death with marked hyperglutaminemia and hyperammonemia.J Inherit Metab Dis. 2019 Nov;42(6):1044-1053. doi: 10.1002/jimd.12048. Epub 2019 Mar 5. J Inherit Metab Dis. 2019. PMID: 30835861 Free PMC article.
-
Targeting CPS1 in the treatment of Carbamoyl phosphate synthetase 1 (CPS1) deficiency, a urea cycle disorder.Expert Opin Ther Targets. 2017 Apr;21(4):391-399. doi: 10.1080/14728222.2017.1294685. Epub 2017 Feb 20. Expert Opin Ther Targets. 2017. PMID: 28281899 Review.
Cited by
-
Clinical and genetic analysis of a case of late onset carbamoyl phosphate synthase I deficiency caused by CPS1 mutation and literature review.BMC Med Genomics. 2023 Jun 26;16(1):145. doi: 10.1186/s12920-023-01569-w. BMC Med Genomics. 2023. PMID: 37365635 Free PMC article. Review.
-
Clinical features and CPS1 variants in Chinese patients with carbamoyl phosphate synthetase 1 deficiency.BMC Pediatr. 2024 Aug 22;24(1):539. doi: 10.1186/s12887-024-05005-5. BMC Pediatr. 2024. PMID: 39174957 Free PMC article.
-
Carbamoyl phosphate synthetase 1 deficiency manifested in an adult treated with prednisone for polymyositis, and cured by live-donor liver transplantation.Mol Genet Metab Rep. 2025 Mar 5;43:101200. doi: 10.1016/j.ymgmr.2025.101200. eCollection 2025 Jun. Mol Genet Metab Rep. 2025. PMID: 40125546 Free PMC article.
-
Carbamoly-phosphate synthetase 1 (CPS1) deficiency: A tertiary center retrospective cohort study and literature review.Mol Genet Metab Rep. 2024 Oct 18;41:101156. doi: 10.1016/j.ymgmr.2024.101156. eCollection 2024 Dec. Mol Genet Metab Rep. 2024. PMID: 39469307 Free PMC article.
-
Variant in the allosteric domain of CPS1 protein associated with effectiveness of N-carbamoyl glutamate therapy in neonatal onset CPS1 deficiency.J Pediatr Endocrinol Metab. 2023 Jul 10;36(9):873-878. doi: 10.1515/jpem-2023-0210. Print 2023 Sep 26. J Pediatr Endocrinol Metab. 2023. PMID: 37427576
References
-
- Summar M.L., Dasouki M.J., Schofield P.J., Krishnamani M.R., Vnencak-Jones C., Tuchman M., Mao J., Phillips J.A. 3rd, physical and linkage mapping of human carbamyl phosphate synthetase I (CPS1) and reassignment from 2p to 2q35. Cytogenet. Cell Genet. 1995;71:266–267. - PubMed
-
- Diez-Fernandez C., Häberle J. Targeting CPS1 in the treatment of carbamoyl phosphate synthetase 1 (CPS1) deficiency, a urea cycle disorder. Expert Opin. Ther. Targets. 2017;21:391–399. - PubMed
-
- Recommended Uniform Screening Panel, Official Web Site of the U.S. Health Resources & Services Administration.
-
- Funghini S., Thusberg J., Spada M., Gasperini S., Parini R., Ventura L., Meli C., De Cosmo L., Sibilio M., Mooney S.D., Guerrini R., Donati M.A., Morrone A. Carbamoyl phosphate synthetase 1 deficiency in Italy: clinical and genetic findings in a heterogeneous cohort. Gene. 2012;493:228–234. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous